Eli Lilly and Co

NYSE:LLYUnited States

Today

Show headlines and story abstract

• *DJ Lilly To Acquire Morphic To Improve Outcomes For Patients With Inflammatory Bowel Disease >LLY MORF, from 3 minutes ago by Dow Jones

  3 minutes ago by Dow Jones
  Companies Mentioned: LLY, MORF

• Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease, from 3 minutes ago by Dow Jones

  3 minutes ago by Dow Jones
  Companies Mentioned: LLY, MORF
  
  The tender offer for all of the outstanding shares of Morphic described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. A solicitation and offer to buy outstanding shares of Morphic will only be made pursuant to the tender offer materials that Lilly and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and Morphic will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF MORPHIC ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF MORPHIC SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all investors and stockholders of Morphic at no expense to them at Lilly's website at investor.lilly.com and (once they become available) will be mailed to the stockholders of Morphic free of charge. Copies of the documents filed with the SEC by Morphic will be available free of charge on Morphic's website, investor.morphictx.com, or by contacting Morphic's investor relations department at chris.erdman@morphictx.com. The information contained in, or that can be accessed through, Morphic's and Lilly's websites is not a part of, or incorporated by reference herein. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the SEC's website at www.sec.gov. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and Morphic file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Lilly and Morphic with the SEC for free on the SEC's website at www.sec.gov.
  

• Eli Lilly, Novo Holdings Participate in Myricx Bio's $114 Million Financing Round, from 2 hours ago by MT Newswires

  2 hours ago by MT Newswires
  Companies Mentioned: LLY, NVO
  04:24 AM EDT, 07/08/2024 (MT Newswires) -- Eli Lilly (LLY) participated in a series A financing round for UK drug developer Myricx Bio that raised 90 million pounds ($114 million), Myricx said Monday. Myricx said the funding was co-led by Novo Holdi...